Abemaciclib + Letrozole + Pembrolizumab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer, Recurrent Endometrial Cancer, TP53
Trial Timeline
Sep 25, 2024 → Mar 1, 2029
NCT ID
NCT06366347About Abemaciclib + Letrozole + Pembrolizumab
Abemaciclib + Letrozole + Pembrolizumab is a phase 2 stage product being developed by Eli Lilly for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06366347. Target conditions include Endometrial Cancer, Recurrent Endometrial Cancer, TP53.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06366347 | Phase 2 | Recruiting |
Competing Products
20 competing products in Endometrial Cancer